<SEC-DOCUMENT>0001213900-26-036923.txt : 20260331
<SEC-HEADER>0001213900-26-036923.hdr.sgml : 20260331
<ACCEPTANCE-DATETIME>20260331083523
ACCESSION NUMBER:		0001213900-26-036923
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260331
FILED AS OF DATE:		20260331
DATE AS OF CHANGE:		20260331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PolyPid Ltd.
		CENTRAL INDEX KEY:			0001611842
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38428
		FILM NUMBER:		26817302

	BUSINESS ADDRESS:	
		STREET 1:		18 HASIVIM STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4959376
		BUSINESS PHONE:		972-74-7195700

	MAIL ADDRESS:	
		STREET 1:		18 HASIVIM STREET
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4959376
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0284288-6k_polypid.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Month of: March 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-38428</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PolyPid Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Translation of registrant&rsquo;s name into
English)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 Hasivim Street</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Petach Tikva 495376, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;Form
20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;Form 40-F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Attached
hereto and incorporated herein is PolyPid Ltd.&rsquo;s (the &ldquo;Registrant&rdquo;) press release issued on March 31, 2026, titled &ldquo;PolyPid
Initiates D-PLEX&#8321;&#8320;&#8320; NDA Submission to the FDA.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The first two paragraphs and the section titled
&ldquo;Forward-Looking Statements&rdquo; in the press release are incorporated by reference&nbsp;into the Registrant&rsquo;s registration
statements on Form F-3 (File No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611842/000121390024009108/ea192572-f3_polypidltd.htm">333-276826</A>,
File No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611842/000121390024058595/ea0208115-f3_polypidltd.htm">333-280658</A>,
File No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611842/000121390024074508/ea0212801-f3_polypidltd.htm">333-281863</A>,
File No.&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/1611842/000121390025004999/ea0227827-f3_polypid.htm">333-284376</A> and
File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611842/000121390025068692/ea0250584-f3_polypid.htm">333-289034</A>) &nbsp;and
Form S-8 (File No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611842/000110465920077735/tm209265d11_s8.htm">333-239517</A>,
File No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611842/000121390023025649/ea176190-s8_polypid.htm">333-271060</A>, File
No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611842/000121390024020445/ea0201047-s8_polypid.htm">333-277703</A>, File No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611842/000121390024058604/ea0208116-s8_polypid.htm">333-280662</A>
and File No. <A HREF="http://www.sec.gov/Archives/edgar/data/1611842/000121390025075646/ea0252816-s8_polypid.htm">333-289570</A>) filed
&nbsp;with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font-size: 10pt"><B>Exhibit&nbsp;No.</B></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: center; width: 9%">99.1</TD>
    <TD STYLE="font-size: 10pt; text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 90%"><A HREF="ea028428801ex99-1.htm">Press Release issued by PolyPid Ltd. on March 31, 2026, titled &ldquo;PolyPid Initiates D-PLEX&#8321;&#8320;&#8320; NDA Submission to the FDA.&rdquo;</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify"><B>POLYPID LTD.</B></TD></TR>
  <TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Date: March 31, 2026</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify">/s/ Jonny Missulawin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">Name:</TD>
    <TD STYLE="width: 32%; text-align: justify"> Jonny Missulawin</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title:</TD>
    <TD STYLE="text-align: justify">Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea028428801ex99-1.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY POLYPID LTD. ON MARCH 31, 2026, TITLED "POLYPID INITIATES D-PLEX100 NDA SUBMISSION TO THE FDA."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="ea028428801_ex99-1img1.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PolyPid Initiates D-PLEX&#8321;&#8320;&#8320;
NDA Submission to the FDA </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><I>PolyPid Submits First Modules as
Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><FONT STYLE="font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><I>U.S. Commercialization Partnership
Negotiations on Track</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><FONT STYLE="font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PETACH TIKVA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd.
(Nasdaq: PYPD) (&ldquo;PolyPid&rdquo; or the &ldquo;Company&rdquo;), an innovative biopharmaceutical company dedicated to improving patient
outcomes by elevating treatment effectiveness, right where care begins, today announced that it has initiated a New Drug Application (&ldquo;NDA&rdquo;)
submission to the U.S. Food and Drug Administration (the &ldquo;FDA&rdquo;) for D-PLEX&#8321;&#8320;&#8320; for the prevention of surgical
site infections (&ldquo;SSIs&rdquo;) in patients undergoing colorectal surgery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The NDA is being submitted under the FDA&rsquo;s Fast Track designation,
which allows for rolling review. The submission includes the Chemistry, Manufacturing and Controls (CMC) and nonclinical sections of the
NDA, with additional components, including the clinical section, expected to be submitted in the second quarter of 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;This submission marks a pivotal milestone for PolyPid as we
advance D-PLEX&#8321;&#8320;&#8320; into its regulatory approval phase,&rdquo; said Dikla Czaczkes Akselbrad, Chief Executive Officer
of PolyPid. &ldquo;Following the positive results from our successful Phase 3 SHIELD II trial and constructive feedback from our previously
announced pre-NDA meeting with the FDA, we are pleased to initiate the NDA submission. We are highly focused on executing toward potential
approval and commercialization, with the goal of bringing D-PLEX&#8321;&#8320;&#8320; to patients undergoing surgery, while advancing
discussions for a U.S. commercialization partnership.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About D-PLEX<SUB>100</SUB></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><SUB>&nbsp;</SUB></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><SUB></SUB></B>D-PLEX<SUB>100</SUB>, PolyPid&rsquo;s
lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to
prevent SSIs. Following the administration of D-PLEX<SUB>100</SUB>&nbsp;into the surgical site, PolyPid&rsquo;s delivery technology,
Kynatrix, pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic
doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional
potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX<SUB>100</SUB>&nbsp;recently demonstrated
positive results in the Phase 3 SHIELD II trial, achieving a statistically significant 60% (p= 0.0013) relative risk reduction in SSI
incidence following abdominal colorectal surgery with large incisions. D-PLEX<SUB>100</SUB>&nbsp;received Breakthrough Therapy Designation
from the&nbsp;FDA&nbsp;for the prevention of SSIs in patients undergoing elective colorectal surgery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About PolyPid</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>PolyPid Ltd. (Nasdaq:&nbsp;PYPD) is an innovative
biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting,
controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a
wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid&rsquo;s lead product, D-PLEX&#8321;&#8320;&#8320;,
successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site
infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of
patient care. For additional Company information, please visit&nbsp;http://www.polypid.com&nbsp;and follow us on&nbsp;Twitter (X)&nbsp;and&nbsp;LinkedIn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as &ldquo;expects,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo; &ldquo;estimates&rdquo;
and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is
using forward-looking statements when it discusses the progress of the rolling NDA submission for D-PLEX&#8321;&#8320;&#8320; and the
expected timing thereof, the Company&rsquo;s expectations regarding potential approval of D-PLEX&#8321;&#8320;&#8320;, and potential
commercial partnership for the U.S. market. Forward-looking statements are not historical facts, and are based upon management&rsquo;s
current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith. However, there can be no assurance that management&rsquo;s expectations, beliefs and projections
will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements.
Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially
from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the
Company, reference is made to the Company&rsquo;s reports filed from time to time with the Securities and Exchange Commission, including,
but not limited to, the risks detailed in the Company&rsquo;s Annual Report on Form 20-F filed on&nbsp;February 25, 2026. Forward-looking
statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements
to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking
information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements,
no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking
statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not
incorporated by reference into this press release.&nbsp;PolyPid&nbsp;is not responsible for the contents of third-party websites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>PolyPid Ltd.<BR>
Ori Warshavsky<BR>
908-858-5995<BR>
IR@Polypid.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Arx Investor Relations<BR>
North American Equities Desk<BR>
polypid@arxhq.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea028428801_ex99-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028428801_ex99-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  F (T# 2(  A$! Q$!_\0
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
